EDGE-Gastric
A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies
- NCT05329766 ↗
- Completed
- Arcus Biosciences, Inc.
- Standard
We haven't built an HCP commentary report on EDGE-Gastric (domvanalimab plus zimberelimab; quemliclustat plus zimberelimab in advanced gastric, gastroesophageal junction or esophageal cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on EDGE-Gastric so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 7 | |
| YouTube | 4 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase 2 Trial to Evaluate the Safety and Efficacy of Combination Therapies in Patients With Advanced Upper Gastrointestinal Tract Malignancies (EDGE-Gastric)
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Gastrointestinal Tract Malignancies
- Interventions
- Domvanalimab; Quemliclustat; Zimberelimab; Fluorouracil; Leucovorin; Oxaliplatin
- Arms
- A1: First Line - Treatment Naïve Participants · Experimental
- A2: First Line - Treatment Naïve Participants · Experimental
- A3 First Line - Treatment Naïve Participants · Experimental
- A4 First Line - Treatment Naïve Participants · Experimental
- B1: Second Line or greater Checkpoint Inhibitor Naïve Participants · Experimental
- B2: Second Line or greater Checkpoint Inhibitor Naïve Participants · Experimental
- Cohort C1: Second Line or greater - Checkpoint Inhibitor Experienced Participants · Experimental
- Enrollment
- 332
- Primary outcomes
- Number of Participants with Adverse Events (AEs)
- Objective Response Rate (ORR) as measured by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
- Sponsor
- Arcus Biosciences, Inc. with Gilead Sciences
- Start
- Jun 10, 2022
- Primary completion
- Sep 7, 2026
- Results posted
- No
- Registry record
- NCT05329766 · updated Oct 26, 2026
Publications
linked from the registry- Janjigian YY, Oh DY, Pelster M, Wainberg ZA, Prusty S, Nelson S, DuPage A, Thompson A, Koralek DO, Sison EAR, Rha SY. Domvanalimab and zimberelimab in advanced gastric, gastroesophageal junction or esophageal cancer: a phase 2 trial. Nat Med. 2025 Dec;31(12):4274-4280. doi: 10.1038/s41591-025-04022-w. Epub 2025 Oct 18. PubMed 41109921